Table 3.

Ongoing adjuvant EGFR TKI trials

Trial	EGFR TKI	Comparison Arm	Population
NCT0140214	erlotinib x 2 years	cisplatin/vinorelbine for 4 cycles	Stage III, EGFR mutations in exon 19 or 21
NCT01405079	gefitinib x 2 years	cisplatin/vinorelbine for 4 cycles	Stage II–III, EGFR exon 19 deletion or L858R
NCT01683175	erlotinib x 2 years	cisplatin/vinorelbine for 4 cycles	Stage III, EGFR exon 19 deletion or L858R
NCT02125240	icotinib x 2 years	placebo	Stage II–III, EGFR exon 19 deletion or L858R, treated with 4 cycles of platinum-based chemotherapy
NCT01746251	afatinib x 2 years	afatinib x 3 months	Stage I–III, EGFR mutation, prior chemotherapy allowed
NCT01929200	icotinib x 2 years	icotinib x 1 year	Stage II–III, EGFR mutation in exon 19 or 21
NCT01996098	chemotherapy followed by icotinib x 6 or 12 months	chemotherapy alone	Stage II–III, EGFR mutation in exon 19 or 21
NCT02194738	erlotinib x 2 years	placebo	Stage IB–III, EGFR mutation
NCT02264210	icotinib x 12 months	observation	Stage IB, EGFR mutation in exon 19 or 21
WJOG6410L	gefitinib x 2 years	cisplatin/vinorelbine	Stage II–III, EGFR exon 19 deletion or L858R